[O:1]1[C:9]2[CH:8]=[CH:7][N:6]=[C:5]([NH:10][C:11](=[O:18])[C:12]3[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=3)[C:4]=2[CH:3]=[CH:2]1.C([Li])CCC.CN(C)[CH:26]=[O:27].[Cl-].[NH4+]>C1COCC1>[CH:26]([C:2]1[O:1][C:9]2[CH:8]=[CH:7][N:6]=[C:5]([NH:10][C:11](=[O:18])[C:12]3[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=3)[C:4]=2[CH:3]=1)=[O:27]7.13 g (30 mmol) N-(Furo[3,2-c]pyridin-4-yl)benzamide (Example 2A) were dissolved in 150 ml dry THF under inert gas atmosphere. At −78° C., 26.4 ml (66 mmol) n-butyllithium solution (2.5 M in hexane) were added dropwise, and the mixture was stirred for 30 min at this temperature. Then, 5.1 ml (66 mmol) dry N,N-dimethylformamide were added dropwise. After addition was completed, the mixture was slowly warmed up to rt, and 300 ml saturated aq. ammonium chloride solution were added. After extraction with 300 ml diethyl ether, the organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure to afford a brown solid. This material was purified by chromatography on silica gel (eluent dichloromethane/methanol 99:1 v/v) to afford 5.2 g (65% of th.) of the title compound as a pale yellow solid [cf. J. B. M. Rewinkel et al., Bioorg. Med. Chem. Lett. 9, 2837-2842 (1999)].